Jazz Pharmaceuticals Operations UK Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as GW Pharma Limited (to 2025)
6
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Use of One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy (US 9,066,920) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Mar 8, 2027The maintenance fee for Use of the Phytocannabinoid Cannabidivarin (CBDV) in the Treatment of Epilepsy (US 9,125,859) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due Apr 27, 2027The maintenance fee for Use for Cannabinoid (US 9,168,278) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 1 fee due Nov 19, 2027The maintenance fee for Use of Cannabinoids in the Treatment of Mental Disorders (US 10,653,641) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 22, 2026
- Sep 22 US 7,968,594 Pharmaceutical Compositions for the Treatment of Pain · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,700,368 | Methods of Purifying Cannabinoids from Plant Material In force · High confidence | In force | High confidence | |
| US 8,481,085 | Pharmaceutical Compositions Comprising Cannabigerol In force · High confidence | In force | High confidence | |
| US 9,168,278 | Use for Cannabinoid In force · High confidence | In force | High confidence | |
| US 9,017,737 | Use of Cannabinoids in Combination with an Anti-Psychotic Medicament In force · High confidence | In force | High confidence | |
| US 8,632,825 | Anti-Tumoural Effects of Cannabinoid Combinations In force · High confidence | In force | High confidence | |
| US 9,522,123 | Use of One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy In force · High confidence | In force | High confidence | |
| US 8,790,719 | Phytocannabinoids in the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 9,675,654 | Phytocannabinoids in the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,799,467 | Use of the Phytocannabinoid Cannabidivarin (CBDV) in the Treatment of Epilepsy In force · High confidence | In force | High confidence | |
| US 9,125,859 | Use of the Phytocannabinoid Cannabidivarin (CBDV) in the Treatment of Epilepsy In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.